With the increasing understanding of cancer-related inflammation, systemic inflammatory response biomarkers, such as the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and C-reactive protein level,12 have been clearly demonstrated to predict the prognoses of cancer patients, including those with non-small cell lung cancer,13 renal cell carcinoma,14 and colorectal cancer.15 However, inflammation prognosis biomarkers only integrate two inflammatory cells. Here, CRP is linked to cancer.